Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
ImmuPharma PLC
IMMCurrent price
1.68 GBX
-0.12 GBX (-6.55%)
Last closed
1.64 GBX
Company
www.immupharma.co.uk
ISIN
GB0033711010
Sector
Healthcare
Industry
Biotechnology
Exchange
London Exchange
Capitalization
6 491 570 GBX
Yield for 12 month
-0.30 %
1Y
3Y
5Y
10Y
15Y
IMM
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the P140 (Lupuzor), a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140 which is in Phase II for chronic inflammatory demyelinating polyneuropathy, a progressive inflammatory condition of the nerves; and P140 in other indications for asthma, gout, periodontitis, and IBD. Its pre-clinical products include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations for serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection treatment. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom. Address: 1 Bartholomew Close, London, United Kingdom, EC1A 7BL
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
386.29 GBXP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-3 763 913 GBX
Last Year
-11 766 410 GBX
Current Quarter
-1 885 858 GBX
Last Quarter
–
Key Figures IMM
1 year
3 years
5 years
10 years
EBITDA
-2 560 935 GBX
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-43 %
PEG Ratio
–
Return On Equity TTM
-111.2 %
Wall Street Target Price
386.29 GBX
Revenue TTM
-70 019 GBX
Book Value
0.006 GBX
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
47.1 %
Dividend Yield
–
Gross Profit TTM
118 452 GBX
Earnings per share
-0.01 GBX
Diluted Eps TTM
-0.01 GBX
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics IMM
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
-93 %Dividend History IMM
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
14.12.2021
Forward Annual Dividend Yield
–
Last Split Factor
1:1
Payout Ratio
–
Last Split Date
17.08.2022
Dividend Date
–
Stock Valuation IMM
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
73.6224
Price Sales TTM
60.7506
Enterprise Value EBITDA
-0.9408
Price Book MRQ
2.4108
Financials IMM
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators IMM
For 52 weeks
0.82 GBX
3 GBX
50 Day MA
1.71 GBX
Shares Short Prior Month
–
200 Day MA
1.85 GBX
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart